These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34709497)

  • 21. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
    Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers.
    Wang Y; Gao Z; Liu Z; Liu G; Qu X; Chen J; Ren X; Xu Z; Yang H
    Expert Opin Biol Ther; 2022 Feb; 22(2):225-234. PubMed ID: 34134579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
    Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
    Blauvelt A; Leonardi CL; Gaylis N; Jauch-Lembach J; Balfour A; Lemke L; Hachaichi S; Brueckmann I; Festini T; Wiland P
    BioDrugs; 2021 Mar; 35(2):229-238. PubMed ID: 33651341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.
    Kimel M; Revicki D; Rao S; Fryback D; Feeny D; Harnam N; Thompson C; Cifaldi M
    Clin Exp Rheumatol; 2011; 29(4):624-32. PubMed ID: 21813060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
    Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
    van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
    Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.
    Lee SH; Park W; Won Lee S; Kim HA; Choe JY; Lee SH; Lee SS; Park SH; Park MC; Sheen DH; Lee HS; Lee YA; Lee Y; Kim TH
    Int J Rheum Dis; 2020 Aug; 23(9):1175-1183. PubMed ID: 32725789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial.
    Gonzalez-Lopez L; Garcia-Gonzalez A; Vazquez-Del-Mercado M; Muñoz-Valle JF; Gamez-Nava JI
    J Rheumatol; 2004 Aug; 31(8):1568-74. PubMed ID: 15290737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
    van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E;
    Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis.
    Rudwaleit M; Gooch K; Michel B; Herold M; Thörner A; Wong R; Kron M; Chen N; Kupper H
    J Rheumatol; 2011 Jan; 38(1):79-86. PubMed ID: 20952469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.
    Luchetti MM; Benfaremo D; Ciccia F; Bolognini L; Ciferri M; Farinelli A; Rossini M; Mosca P; Triolo G; Gabrielli A
    World J Gastroenterol; 2017 Oct; 23(39):7139-7149. PubMed ID: 29093622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
    van der Heijde D; Joshi A; Pangan AL; Chen N; Betts K; Mittal M; Bao Y
    Rheumatology (Oxford); 2016 Jan; 55(1):80-8. PubMed ID: 26316575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.